The Future of Myelodysplastic Syndrome
An oncologist discusses the future of myelodysplastic syndrome, including upcoming studies and potential treatments.
Emerging First-Line Treatments for High-Risk Myelodysplastic Syndrome
Dr. Naval Daver provides insight on the emerging first-line treatment options for high-risk myelodysplastic syndrome and breaks down clinical trial data.
Treating Patients with High-Risk Myelodysplastic Syndrome
An expert details the treatment options for high-risk myelodysplastic syndrome.
Treatment Options for Low-Risk Myelodysplastic Syndrome
Naval Daver, MD, illustrates the goals of treatment and treatment options for low-risk myelodysplastic syndrome.
Diagnosis of Myelodysplastic Syndrome
A key opinion leader describes how myelodysplastic syndrome is diagnosed, the typical presenting symptoms, and the methods of risk assessment.
An Overview of Myelodysplastic Syndrome
Naval Daver, MD, explains myelodysplastic syndrome, including risk factors and potential complications.
Discussing Rationale of Azacitidine Plus Maintenance Therapy in AML
Naval Daver, MD, explains the rationale for the phase II QUAZAR trial, which assessed the efficacy and safety of azacitidine in patients with acute myeloid leukemia.
Agents Under Investigation in AML
Naval Daver, MD, assistant professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses agents being investigated in acute myeloid leukemia (AML).
2 Clarke Drive Cranbury, NJ 08512